166 related articles for article (PubMed ID: 12201834)
1. The treatment of a thyrotropin-secreting pituitary macroadenoma with octreotide in twin pregnancy.
Blackhurst G; Strachan MW; Collie D; Gregor A; Statham PF; Seckl JE
Clin Endocrinol (Oxf); 2002 Sep; 57(3):401-4. PubMed ID: 12201834
[TBL] [Abstract][Full Text] [Related]
2. Thyrotropin secreting pituitary adenoma effectively treated with octreotide.
Fukuda T; Yokoyama N; Tamai M; Imaizumi M; Kimura H; Tominaga T; Ashizawa K; Kiriyama T; Yoshimine H; Ohishi K; Eguchi K
Intern Med; 1998 Dec; 37(12):1027-30. PubMed ID: 9932634
[TBL] [Abstract][Full Text] [Related]
3. Successful pregnancy in an infertile woman with a thyrotropin-secreting macroadenoma treated with somatostatin analog (octreotide).
Caron P; Gerbeau C; Pradayrol L; Simonetta C; Bayard F
J Clin Endocrinol Metab; 1996 Mar; 81(3):1164-8. PubMed ID: 8772594
[TBL] [Abstract][Full Text] [Related]
4. TSH-secreting pituitary macroadenoma: rapid tumor shrinkage and recovery from hyperthyroidism with octreotide.
Fischler MP; Reinhart WH
J Endocrinol Invest; 1999 Jan; 22(1):64-5. PubMed ID: 10090139
[TBL] [Abstract][Full Text] [Related]
5. Thyrotropin secreting pituitary adenoma associated with hypopituitarism and diabetes insipidus in an adolescent boy.
Phillip M; Hershkovitz E; Kornmehl P; Cohen A; Leiberman E
J Pediatr Endocrinol Metab; 1995; 8(1):47-50. PubMed ID: 7584697
[TBL] [Abstract][Full Text] [Related]
6. Successful pregnancy in a woman with acromegaly treated with somatostatin analog (octreotide) prior to surgical resection.
Mozas J; Ocón E; López de la Torre M; Suárez AM; Miranda JA; Herruzo AJ
Int J Gynaecol Obstet; 1999 Apr; 65(1):71-3. PubMed ID: 10390105
[TBL] [Abstract][Full Text] [Related]
7. Use of somatostatin analogue in management of a thyrotrophin secreting pituitary adenoma.
Stiles MK; Conaglen JV; Speed J; Chatterton B
Aust N Z J Med; 1996 Feb; 26(1):122-3. PubMed ID: 8775545
[No Abstract] [Full Text] [Related]
8. [Octreotide in the diagnosis and treatment of pituitary thyrotropin-secreting adenoma].
Chen S; Li M; Lian XL; Zeng ZP; Dai WX; Li F; Yu W; Wang RZ
Zhonghua Nei Ke Za Zhi; 2006 Nov; 45(11):910-3. PubMed ID: 17313878
[TBL] [Abstract][Full Text] [Related]
9. Treatment of thyrotropin-secreting pituitary adenomas with octreotide.
Shimatsu A; Murabe H; Kamoi K; Suzuki Y; Nakao K
Endocr J; 1999 Feb; 46(1):113-23. PubMed ID: 10426575
[TBL] [Abstract][Full Text] [Related]
10. Pathological study of thyrotropin-secreting pituitary adenoma: plurihormonality and medical treatment.
Teramoto A; Sanno N; Tahara S; Osamura YR
Acta Neuropathol; 2004 Aug; 108(2):147-53. PubMed ID: 15185102
[TBL] [Abstract][Full Text] [Related]
11. Reduction in size of a thyrotropin-secreting pituitary adenoma treated with octreotide acetate (somatostatin analog).
Lee EJ; Kim KR; Lim SK; Lee HC; Kim DI; Kim SH; Huh KB
Eur J Endocrinol; 1994 Jul; 131(1):109-12. PubMed ID: 8038902
[TBL] [Abstract][Full Text] [Related]
12. Management of a pregnant woman with thyrotropinoma: a case report and review of the literature.
Perdomo CM; Árabe JA; Idoate MÁ; Galofré JC
Gynecol Endocrinol; 2017 Mar; 33(3):188-192. PubMed ID: 27910710
[TBL] [Abstract][Full Text] [Related]
13. Shrinkage of thyrotrophin secreting pituitary adenoma treated with octreotide.
Orme SM; Lamb JT; Nelson M; Belchetz PE
Postgrad Med J; 1991 May; 67(787):466-8. PubMed ID: 1852668
[TBL] [Abstract][Full Text] [Related]
14. Shrinkage of a primary thyrotropin-secreting pituitary adenoma treated with the long-acting somatostatin analogue octreotide (SMS 201-995).
Warnet A; Lajeunie E; Gelbert F; Duet M; Chanson P; Cophignon J; Harris AG
Acta Endocrinol (Copenh); 1991 Apr; 124(4):487-91. PubMed ID: 2031445
[TBL] [Abstract][Full Text] [Related]
15. Preoperative long-acting octreotide treatment for invasive thyrotropin-secreting pituitary macroadenoma after previous radioiodine thyroid ablation.
Gruszka A; Zielinski GM; Kunert-Radek J
J Clin Neurosci; 2014 Feb; 21(2):340-2. PubMed ID: 23958483
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of the long-acting octreotide formulation (octreotide-LAR) in patients with thyrotropin-secreting pituitary adenomas.
Caron P; Arlot S; Bauters C; Chanson P; Kuhn JM; Pugeat M; Marechaud R; Teutsch C; Vidal E; Sassano P
J Clin Endocrinol Metab; 2001 Jun; 86(6):2849-53. PubMed ID: 11397898
[TBL] [Abstract][Full Text] [Related]
17. Somatostatin receptor subtypes mRNA in TSH-secreting pituitary adenomas: a case showing a dramatic reduction in tumor size during short octreotide treatment.
Horiguchi K; Yamada M; Umezawa R; Satoh T; Hashimoto K; Tosaka M; Yamada S; Mori M
Endocr J; 2007 Jun; 54(3):371-8. PubMed ID: 17420609
[TBL] [Abstract][Full Text] [Related]
18. Primary treatment of a combined somatotropin- and thyrotropin-secreting pituitary tumour with octreotide.
Walsh JP; Glatthaar C; Pullan PT
Aust N Z J Med; 1996 Feb; 26(1):124-5. PubMed ID: 8775546
[No Abstract] [Full Text] [Related]
19. [Octreotide in the treatment of thyrotropin-secreting pituitary adenomas].
Podoba J; Hnilica P; Makaiová I; Kovácová S; Rybár M; Gecík K; Belan V; Steno J
Vnitr Lek; 1997 Sep; 43(9):607-10. PubMed ID: 9750471
[TBL] [Abstract][Full Text] [Related]
20. A rare case and a rapid tumor response to therapy: dramatic reduction in tumor size during octreotide treatment in a patient with TSH-secreting pituitary macroadenoma.
Erem C; Hacihasanoglu A; Sari A; Onder Ersöz H; Ukinç K; Fidan S
Endocrine; 2004 Nov; 25(2):141-5. PubMed ID: 15711028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
